Screener
TG Therapeutics TGTX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's total liabilities?
- TG Therapeutics (TGTX) reported total liabilities of $1.04B in Q2 2026.
- How has TG Therapeutics's total liabilities changed year-over-year?
- TG Therapeutics's total liabilities increased by 143.0% year-over-year, from $426.18M to $1.04B.
- What is the long-term trend for TG Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), TG Therapeutics's total liabilities has grown at a 31.3% compound annual growth rate (CAGR), from $106.29M to $415.23M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about TG Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude